From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Past Events

Real-World Evidence Webinar Series: Considerations Regarding Non-Interventional Studies for Drug and Biological Products
The Reagan-Udall Foundation for the FDA, in collaboration with the Food and Drug Administration (FDA), hosted a public webinar as part of a series of webinars for FDA-issued guidance related to real-world evidence (RWE).
Natural History Studies and Registries in the Development of Rare Disease Treatments
The Reagan-Udall Foundation for the FDA, in collaboration with FDA’s Rare Diseases Team within the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine; Office of New Drugs; Center for Drug Evaluation and Research and the National Institutes of Health’s Division of Rare Diseases Research Innovation within the National Center for Advancing Translational Sciences, is hosting a public workshop.
2024 Annual Public Meeting
Each year, the Reagan-Udall Foundation for the FDA conducts an annual public meeting to discuss its activities in support of the U.S. Food and Drug Administration.
Qualifying Biomarkers to Support Rare Disease Regulatory Pathways
Qualifying Biomarkers to Support Rare Disease Regulatory Pathways
-
Advancing Psychedelic Clinical Study Design
Advancing Psychedelic Clinical Study Design Virtual Public Meeting Day 1: January 31, 2024 | 10am-2pm (eastern)
2023 Innovations in Regulatory Science Awards
Front-of-Package Nutrition Labeling
Front-of-Package Nutrition Labeling Virtual Public Meeting
Integrating Clinical Studies Into Health Care Delivery: Post-Market Evidence Generation for Medical Products
Integrating Clinical Studies Into Health Care Delivery: Post-Market Evidence Generation for Medical Products Virtual Public Meeting
Virtual Public Meeting: Strategies for Improving Public Understanding of FDA-Regulated Products
Strategies for Improving Public Understanding of FDA-Regulated Products Virtual Public Meeting
Public Meeting: Mitigating Risks from Human Xylazine Exposure
Mitigating Risks from Human Xylazine Exposure Public Meeting: In-person and Virtual